Investors remain leery of the biotech industry

Oh, those fickle biotech investors. In Vivo says that biotech investors haven't proven to be very bullish about the money that pharma companies are pumping into emerging developers through new collaborations. To make its point, In Vivo highlights a series of big-dollar deals at public biotech companies and their subsequent drop in stock price.

To be fair, notes In Vivo, the equities market has been shaken up recently. But the good partnership news should have overcome the Wall Street jitters, insists the blog. It's all a sign that the market no longer cares about such market validations.

- read the analysis in In Vivo

Related Articles:
Pharma noshes at the biotech buffet. Report
VC adds billions in its pursuit of biotech ventures. Report
Billion-dollar baby: Biotech still on a roll with VC funds. Report
Biotech stocks surge as investors anticipate buyouts. Report

Suggested Articles

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.